-
U.S. Boulder Study: 15th Subject Enrolled
-
Boulder: 13th and 14th Subjects Enrolled
-
U.S. Boulder Study: 11th Subject Treated; 12th Enrolled; IRB Approves Protocol Amendment
-
Boulder: Three More Subjects Enrolled; Study Size Increased to 23 Subjects
-
Boulder: Sixth and Seventh Subjects Treated, Amendment Submitted to FDA and IRB
-
Boulder: Fifth Subject Treated, Sixth Subject Enrolled
-
Boulder: Fifth Subject Enrolled; MDMA Encapsulated for New Dose Group
-
Boulder: Fifth Subject Treated; DEA Approves Expanded Protocol
-
Boulder: Fourth Subject Enrolled and Treated; Fifth Subject Enrolled
-
Boulder: Second and Third Subjects Treated
-
Boulder: Second and Third Subjects Enrolled; IRB Approves Amended Protocol
-
Boulder: Amended Protocol Submitted to FDA and IRB
-
U.S. Boulder Study: First Subject Receives MDMA-Assisted Therapy
-
U.S. Boulder Study: First Subject Enrolled, MDMA Encapsulated at Pharmacy
-
U.S. Boulder Study: DEA MDMA Order Forms Arrive at Study Site
-
U.S. Boulder Study: DEA MDMA Order Forms Arrive at Study Site
-
U.S. Boulder Study: IRB Approves Amended Protocol; Site Prepares for Subject Screening
-
U.S. Boulder Study: DEA Approves Schedule I License for Study Physician
-
U.S. Boulder Study: DEA Inspects Study Site for MDMA License
-
U.S. Boulder Study: Business License Issued for Study Site